Israeli Womens Health Startups 2025 List

Our company's founders have over a decade of experience in womens health, clinical research, medical device, research and development and business development. We understand that seeking solutions for unmet needs in women's health is not a one-size-fits-all approach. Urinary incontence is a problem that affects 37% of women between the ages of 20-45 over the age of millions of women worldwide.Today women of all ages are living more active lives and we are driven to making sure nothing stand in their way.

Aipsy is an AI-powered mental health checkup and monitoring application designed to help individuals track, understand, and improve their psychological well-being through regular, low-friction self-assessments. The platform uses short voice-based check-ins to analyze emotional markers such as tone, rhythm, and speech dynamics, providing users with ongoing insights into their mental and emotional state.

Aipsy enables continuous tracking of mental health trends over time, helping users recognize early signs of stress, emotional overload, or burnout. Based on these checkups, the app delivers personalized, non-clinical recommendations focused on emotional regulation, self-reflection, and healthy coping strategies.

Built with a privacy-first, on-device AI architecture, Aipsy ensures that sensitive data remains under the user’s control. The platform does not provide diagnoses or treatment, but serves as a supportive tool for mental health awareness and prevention. Aipsy’s mission is to make mental health monitoring accessible, proactive, and safe for everyday use.

Algamed Therapeutics provide solutions for the most common vagina issues: Dryness Infections and Pain based on our patented bioactive technology platform based on Algae. With medical device grade products in the market and loyal customers we are now ready to expand our reach globall

Eating disorder care relies on subjective self-reports. The result is unreliable, retrospective and costly treatment management processes. We solve this by providing effortless, objective, real-time monitoring – by deploying machine learning on biomarkers from commercial level wearables.

Ark Surgical is an FDA-cleared women’s health MedTech company now launching U.S. commercialization of LapBox®, its differentiated tissue containment platform for minimally invasive gynecologic surgery. LapBox® is designed to help surgeons perform laparoscopic and robotic hysterectomy and myomectomy while reducing the risk of tissue dissemination during tissue extraction—supporting safer care in an environment of heightened patient-safety and medico-legal scrutiny. The company’s dual-wall containment technology enables contained workflows for both manual and power tissue morcellation, providing a scalable solution for hospitals seeking to preserve the benefits of minimally invasive surgery while strengthening safety standards. Ark is building adoption through surgeon champions, clinical evidence generation, and targeted health-system entry, with a strategy oriented toward strategic partnerships with leading global women’s health and surgical device players. With clear regulatory status, strong clinical pull, and a large addressable procedure base, Ark is positioned to become a category leader in safe minimally invasive tissue extraction.

BAIBYS™ revolutionizes fertility treatment with cutting-edge AI and micro-robotics. Our autonomous system transforms sperm selection for IVF, delivering unparalleled efficiency and precision using high-magnification. By automating the process to a few minutes (including the physical pick-up and relocation into target droplets), we dramatically reduce time and costs while adhering to WHO morphology and motility criteria. The user-friendly console and disposable cartridges streamline laboratory workflows, boosting clinic productivity and revenue.
Our innovation will elevate IVF success rates, minimize birth defects, and alleviate the economic strain on healthcare systems. By freeing up embryologists and making IVF more accessible globally, BAIBYS™ opens doors for countless families dreaming of healthy babies.
Team up with BAIBYS™ and be part of a groundbreaking solution that not only disrupts the fertility market but also creates a profound social impact. Join us in shaping the future of reproductive medicine and helping more families experience the joy of parenthood.

Buzzy is an AI-powered, cloud-based platform that provides real-time mental health insights to care providers. By analyzing physiological, behavioral, and environmental data, Buzzy identifies early signs of psychological decline and helps prioritize care. Our solution integrates seamlessly with wearables and existing workflows, enabling proactive intervention, improving outcomes, and reducing clinician burnout. Designed for scalability and reimbursement, Buzzy serves health providers, insurers, and care providers.

Carmel Diagnostics is an innovative SME specialising in advanced biomedical diagnostics based on using measurement of oxidative stress with ThermoChemiLuminescece (TCL) technology. Our core activity is developing non-invasive, rapid assays that quantify oxidative stress and related biomarkers in biological fluids. This proprietary platform enables early detection, patient stratification and treatment monitoring across multiple clinical domains. We continuously invest in R&D, translating scientific insights into clinically validated solutions, including successful studies in fertility and preeclampsia. Our innovation-driven approach, strong IP portfolio and commitment to market-oriented research position us squarely within the definition of an innovative, technology-intensive SME.

Novel approach to managing autoimmune diseases through skin surface protein profiling, integrating women’s physiological features into predictive medicine — an element often ignored in current models.
DermaBio is well positioned for strategic acquisition by a major diagnostics company or national lab network. Our platform aligns with key priorities: high-volume testing, clinical utility, payer value, and scalability across multiple autoimmune conditions. As we move toward CLIA certification and commercial pilots, we are building the foundation for seamless integration into existing lab workflows.

Donnie Life Ltd. is an innovative Israeli FemTech startup dedicated to transforming the childbirth experience by addressing one of the most common physical complications of vaginal delivery: perineal tearing. Founded in 2024 and headquartered in Tel Aviv, the company has developed a unique, non-invasive medical device designed to support the perineal tissue during the final stages of labor.
The proprietary multi-layered technology works by distributing the physical pressure of childbirth across a wider surface area, significantly reducing the risk of high-degree (3rd and 4th grade) tears and long-term postpartum complications. Developed in collaboration with Clalit Health Services and backed by a team of senior medical professionals, Donnie Life aims to integrate its solution into delivery rooms worldwide, providing a safe, preventive alternative to current reactive treatments. The company is currently in the seed stage, focusing on clinical validation and scaling its B2B model to global healthcare providers.

Chronic conditions like cancer and endometriosis remain difficult to diagnose accurately due to the limitations of current imaging tools. Cancer is the most misdiagnosed of the 'big three' conditions, and 75% of endometriosis patients receive an incorrect diagnosis and are forced to undergo diagnostic surgery. While MRI and PET-CT often miss small findings, ultrasound is highly operator-dependent and inconsistent, leaving a critical gap in early and reliable diagnosis.
Revealan™, our robotic ultrasound imaging platform, seamlessly integrates with any off-the-shelf ultrasound device to enable operator-agnostic, automated, AI-enabled, high-resolution 3D imaging. The robotic scan output is a series of standardized medical images with a density at least 10 times higher than that of an MRI. Our solution represents a transformative leap forward not only in the diagnosis and monitoring of various conditions but also in surgical planning. It stands alone as the premier solution offering comprehensive mapping to facilitate personalized treatment.

Escala is a medical technology company dedicated to revolutionizing the treatment of Pelvic Organ Prolapse (POP), a condition affecting nearly half of women worldwide. The company’s flagship product, Mendit, is the first FDA-cleared, incision-free repair solution designed to shift the standard of care from invasive surgery to a simple, office-based procedure.
Founded in 2014, Escala focuses on providing a "mid-path" alternative for the millions of women who currently wait for their condition to deteriorate before undergoing surgery. The Mendit system utilizes a specialized anchoring and fixation device to restore anatomical position in a procedure that typically takes less than 10 minutes and can be performed under local anesthesia. Escala is committed to improving global access to durable, minimally invasive treatments that enhance women’s quality of life and clinical outcomes.

Femme Medical is an Israeli women’s health startup developing a first of its kind intravaginal therapeutic device for urinary leakage, a condition affecting one in three women and significantly impacting quality of life. Current options are either time consuming, invasive, or provide only partial relief. Femme introduces a new category of care: a passive, non invasive, tampon like device designed to provide immediate support during daily activities while also helping train and strengthen pelvic floor function over time.

The company is preparing its First in Human clinical trial at Ichilov Hospital and advancing a scalable regulatory pathway toward FDA 510k clearance. Femme Medical’s solution aims to offer an accessible, discreet, and easy to use alternative to surgery or long term pad dependence.

Led by CEO Limor Halay and supported by the Israel Innovation Authority and private investors, Femme Medical is positioned to address a major unmet need in a rapidly growing global market and redefine care for pelvic floor disorders.

FEMSelect developed and is commercializing EnPlace® – a minimally invasive, mesh-free approach to prolapse repair that has FDA clearance and CE Mark. 50% of women will suffer from prolapse in her lifetime, experiencing life-altering symptoms such as incontinence, pain and difficulty with sexual intercourse. With EnPlace, women experience minimal pain and recover in days. FEMSelect is in commercial phase in both Israel and the US where it has a Center for Medicare and Medicaid (CMS) reimbursement code for the procedure and dozens of hospitals/ASC’s regularly purchasing.

Virtual biopsy system for accurate endometrial diagnosis and dating, in particular during IVF treatments.

Formidable is a digital health technology company developing software systems for healthcare organizations in regulated environments. The company builds applications that integrate simply with existing electronic medical record and healthcare management systems, without requiring changes to established clinical workflows.

Formidable’s solutions support flexible integration models, including API connections, SDK-based integration, and standalone web applications, allowing each organization to choose the implementation approach that best fits its operational and regulatory needs. The platform is designed to support the management of regulatory requirements and complex healthcare processes within the healthcare system.

Formidable works with hospitals, health funds, pharmacies, and other healthcare organizations to deliver end-to-end digital solutions for complex system challenges, enabling healthcare organizations to transition more efficiently and reliably to digital processes, including in care settings that involve multiple providers, such as women’s health.

Freeda.AI is a FemTech company developing an artificial intelligence–driven platform to support women in perimenopause and menopause. The company addresses the significant treatment gap in menopause care, a domain characterized by underdiagnosis, fragmented care pathways, and limited access to continuous support, despite its substantial health, economic, and workforce impact.

Freeda.AI’s platform is designed to operate across multiple deployment models: as a standalone digital product for direct use, as part of an integrated medical service alongside healthcare professionals, or as an embedded infrastructure component within employer, insurer, or healthcare system offerings. The company operates primarily in a B2B2C model, enabling early intervention, longitudinal symptom management, and improved quality of life and functional outcomes.

The platform emphasizes scalability, accessibility, and cost efficiency, with the goal of reducing avoidable health deterioration, productivity loss, and pressure on primary and specialist care services associated with menopause.

Gals Bio is turning the monthly bleeding into liquid biopsy

GyneCheck is developing a novel at-home gynecological diagnostic platform designed to improve access, comfort, and continuity of women’s healthcare. The company’s solution enables women to perform guided gynecological examinations at home using a proprietary device, while allowing clinicians to remotely review high-quality visual data as part of clinical care.

GyneCheck addresses a critical gap in women’s health: delayed diagnosis and low adherence to gynecological screening caused by discomfort, limited access to care, and clinic-based barriers. By shifting key elements of gynecological assessment to the home, the platform aims to support earlier detection, improve patient engagement, and enable more continuous follow-up.

The company has completed initial pilot testing, demonstrating strong user satisfaction and reliable device performance. GyneCheck is advancing product development with a focus on integrating AI-based clinical decision support tools intended to assist physicians in interpreting visual data and supporting informed clinical assessment. The company is also preparing for its Seed round while continuing clinical validation and regulatory readiness efforts.

Gynica is a biopharmaceutical company developing the first pharmaceutical-grade cannabinoid-based therapy for gynecological disorders, starting with endometriosis.
The company has completed extensive preclinical validation and IND-enabling design work and is Phase-1–ready in the U.S.

Gynica’s IP portfolio covers unique compositions, delivery methods, and multiple follow-on indications across pelvic and vaginal health. Beyond its lead therapeutic program, the company is also evaluating commercial expansion opportunities in the wellness, nutraceutical, and consumer health space based on its formulations and delivery platforms. Gynica’s mission is to redefine care for underserved women’s health conditions through rigorous science, regulatory-anchored development, and globally scalable therapeutic innovation.

Gyntools provides GYNI, a point-of-care, AI based, rapid and accurate diagnostic system for vaginitis, a common medical condition that is misdiagnosed today in 50% of first clinic visits.

Harmony is a women’s health technology company developing a non-invasive wearable patch for continuous hormone monitoring. The patch passively samples volatile biomarkers emitted from the skin and uses a coated nanoarray sensor with AI-driven analytics to translate chemical fingerprints into real-time hormone trends. Harmony’s platform enables a “Hormonal Digital Twin,” a personalized, dynamic model of each woman’s endocrine profile that supports predictive insights for clinicians and users. The first target market is fertility and IVF, where clinical decisions depend on accurate hormones yet today require frequent blood draws and clinic visits. By enabling continuous, remote monitoring, Harmony aims to improve treatment timing and personalization, reduce clinical burden, and enhance patient experience. The same hardware and analytics are designed to expand to additional indications such as endometriosis, PCOS, and menopause, supporting earlier detection, longitudinal monitoring, and data-driven endocrine care.

IMMA is a women’s health technology company developing a self-operated transvaginal ultrasound solution designed for home use under physician control. The system enables women to perform pelvic ultrasound examinations autonomously while remaining fully integrated into standard medical care pathways. By shifting routine gynecologic and fertility imaging from clinics to the home, IMMA addresses major challenges in access, capacity constraints, patient burden, and continuity of monitoring, particularly in infertility treatment, early pregnancy follow-up, and chronic gynecologic conditions.

IMMA’s technology is based on a motorized, standardized probe movement architecture that supports reproducible imaging and medical oversight, without requiring a trained sonographer manipulating the probe at the time of the exam. The platform is developed with a strong emphasis on clinical validation, regulatory compliance, and reimbursement readiness. IMMA’s mission is to modernize pelvic imaging by making it more accessible, patient-centered, and compatible with evolving models of women’s healthcare delivery.

We are a women-led impact tech company building a scalable, trauma-informed web platform for emotional processing and trauma prevention. Our technology responds to the growing mental health crisis by offering proactive, accessible digital tools designed for real-life stress, uncertainty, and crisis.

The platform delivers structured digital journeys, guided content, and secure community features that support real-time emotional processing and reduce the risk of long-term trauma. Built with a human-centered and data-informed approach, it prioritizes accessibility, privacy, and adaptability across diverse populations.
Emerging from documentary and impact-driven practice, our company bridges storytelling, technology, and social innovation. We work with NGOs, public institutions, and mission-aligned partners to integrate trauma-aware solutions into education, community resilience, and mental health prevention systems.
Our goal is to make trauma prevention a core layer of digital infrastructure — scalable, inclusive, and designed for today’s reality.

Kanso’s proprietary “Molecular 2-Factor Authentication” platform combines isothermal amplification with a unique molecular labeling reaction, delivering lab-grade sensitivity, high specificity, multiplexing, and point mutation detection for antimicrobial resistance. A microfluidics-free design simplifies manufacturing and reduces cost, while a compact, plug-and-play system enables same-visit results in the doctor’s office with no setup fee. By shifting testing revenue from central labs to care providers, Kanso aims to create a compelling financial incentive for adoption alongside better patient care. Clinical validation on patient samples has already demonstrated robust performance, with our vision to transform women’s health starting with STIs and expanding to vaginitis and beyond.

Latica Med has developed a non-invasive acoustic-pulse technology and medical device that enhances endometrial receptivity to boost embryo implantation followed In-vitro fertilization procedure or other fertilization process

Women were never unpredictable – medicine simply lacked the data to understand their physiology. Levana builds the missing clinical intelligence layer that transforms psychiatric dosing from guesswork into daily, data-backed precision. Insurers and clinicians who adopt Levana gain a proprietary view of treatment patterns no one else has, enabling better outcomes, lower costs, and a differentiated standard of care in women’s mental health. For women, Levana finally delivers what psychiatric medication promised: stability, clarity, and consistent relief every day of the month.

LiveKidney Bio is a regenerative medicine, clinical-stage company, aiming to improve the health span and lifespan for kidney patients worldwide. The company’s products are based on proprietary, cell-shielding formulations of mesenchymal stromal cells (MSCs) that promote the continuous and constant release of therapeutic bioactive compounds, producing beneficial systemic and multiorgan effects via unique routes of administration. The company’s products modulate the immune system, reduce inflammation and fibrosis and improve mitochondrial activity, thereby improving kidney function. Our lead product candidate, LK-01 is administered into the subcutaneous tissue and intended to treat autoimmune related kidney disease, including lupus nephritis, IgA nephropathy, rheumatoid arthritis and systemic sclerosis that disproportionately affect women. Initial clinical trials with LK-01 in the US and Israel focus on lupus nephritis that occurs in 60% of lupus patients, predominantly affecting women of childbearing age, with promising safety and efficacy results.

Melody 2.0 (#מדברות_פֶּרִי) is a women’s health infrastructure focused on perimenopause and the menopausal transition, grounded in scientific, clinical, and evidence-based practice. Perimenopause is a universal, high-impact health transition experienced by all women, yet it remains widely underdiagnosed and undertreated. It can begin in the mid-30s, affecting physical health, mental wellbeing, daily functioning, and long-term health outcomes.

Melody 2.0 equips women with the knowledge and tools needed to identify symptoms, understand underlying biological, hormonal, and psychological changes, and make informed decisions about care and support.

The infrastructure integrates education aligned with global clinical guidelines, AI-enabled navigation, CBT-informed behavioral frameworks, and real-world data collection through digital tools and large-scale surveys. By translating science, clinical research, and lived experience into structured, scalable tools, Melody 2.0 supports women, employers, and healthcare stakeholders - and contributes evidence-driven insight to improve women’s health at scale.

MICA Artificial Intelligence Ltd. is an Israeli medical AI company developing advanced solutions for breast cancer detection, with a specific focus on women with dense breast tissue. Founded in 2020 and headquartered in Tel Aviv, MICA was established by a multidisciplinary team of experts in radiology, oncology, and artificial intelligence. The company’s flagship technology, M2C™, is an AI-based software that analyzes contrast-enhanced mammography–like information derived from standard mammography images, eliminating the need for contrast agents or additional imaging procedures. M2C™ is designed to support radiologists by improving cancer detection sensitivity while maintaining workflow efficiency and patient safety. MICA operates under a B2B model, partnering with hospitals, imaging centers, and healthcare providers. The company holds ISO 13485 certification and has received regulatory approvals in Israel and Argentina, with ongoing efforts toward U.S. FDA clearance. MICA collaborates with leading clinical institutions, including Sheba Medical Center, to validate its technology through clinical studies and real-world use.

MyLee by MyMilk is an innovative device and app transforming at-home and remote breastfeeding care. By sensing few milk drops, MyLee identifies early trends in breastfeeding effectiveness or challenges, empowering mothers to proactively navigate their breastfeeding journey.

MyVoice AI is an impact-driven AI startup developing a personalized communication platform for non-verbal individuals, with a strong focus on the autistic community. The platform enables users to express themselves through adaptive, AI-powered voices and communication tools tailored to their identity, preferences, and emotional context.

From a Women’s HealthTech perspective, MyVoice AI addresses a critical and often overlooked population: autistic girls and women, who are frequently underdiagnosed, misdiagnosed, and underserved by existing assistive technologies. By enabling self-expression, autonomy, and participation in healthcare, education, and daily decision-making, MyVoice AI supports mental well-being, dignity, and inclusion across the lifespan.

The platform is designed to work with caregivers, therapists, and families, while centering the user’s own voice and choices. MyVoice AI aims to redefine how non-verbal communication technologies are built—moving from generic solutions to deeply personalized, human-centered AI.

Nayara builds clinically safe, emotionally intelligent AI companions that support patients through complex healthcare journeys and help providers, payors, and medtech companies deliver better outcomes with less operational burden. Our platform combines disease-specific clinical accuracy with human-like support—guiding patients step-by-step, proactively checking in, collecting structured information, and escalating issues appropriately when needed. What differentiates Nayara is our set of reusable building blocks—clinical workflow logic, safety/monitoring, proactive behaviors, and longitudinal personalization—already shipped and tested with real patients. The result is not another chatbot, but an outcomes-focused companion that improves patient experience while generating measurable ROI through reduced inbound load, better pathway adherence, and higher-quality between-visit care.

Neuro-Joy Ltd. is a medtech startup at the forefront of non-invasive neurostimulation therapies for mental health. We are developing a patent-pending facial neurostimulation device designed for home use—a drug-free, non-invasive, and non-addictive solution for treating anxiety and sleep disorders, conditions that affect hundreds of millions globally.

Nevia Bio is a diagnostics company focused on transforming early detection, monitoring and treatment guidance for gynecological conditions. By harnessing the unique biological properties of vaginal fluid as a liquid biopsy, we aim to deliver earlier, more accurate, and more accessible diagnostic solutions-starting with ovarian cancer and expanding to the full spectrum of gynecological indications.

​Using AI and a multi-omics approach, we are challenging conventional assumptions in cancer care and pioneer a novel, proximity-based, non-invasive approach that gives women better outcomes, more time, and greater agency over their health.

Pioneering precision in surgical oncology, NUTEK develops an AI-powered, handheld hyperspectral imaging scanner that enables real-time detection of residual cancerous tissue on the patient's body during surgery. Its technology transforms tumor removal from subjective estimation to objective, data-driven precision, reducing re-operations and improving patient outcomes. Backed by a multidisciplinary leadership team and proven clinical validation, NUTEK is positioned to disrupt the multi-billion-dollar guided surgery market.

Pink Star is developing an AI-driven decision support platform for breast MRI, designed to improve early cancer detection while reducing unnecessary follow ups, variability in interpretation, and radiologist burnout. Built at Sheba Medical Center, one of the world’s top ten hospitals, Pink Star is grounded in real world clinical practice and unmet needs.

By improving diagnostic accuracy and consistency, Pink Star aims to enable earlier detection, better patient outcomes, and more efficient use of radiology resources. The company’s vision is to meaningfully impact women’s health while creating a scalable, clinically validated platform with strong global commercial potential.

Point6 Bio is a precision diagnostics company developing the first AI-powered, biology-based blood test for early and accurate autism diagnosis. By analyzing specific biological markers in children’s plasma with proprietary machine-learning models, the test provides an objective complement to behavioral assessments that are often slow and subjective—particularly for children whose behavioral presentation differs from diagnostic norms, including girls and those from culturally or linguistically diverse backgrounds. By directly detecting autism-related molecular changes, Point6 Bio overcomes key diagnostic biases, enabling more accurate and equitable diagnosis across sexes and populations. This approach reduces diagnostic delays, supports clinicians with objective evidence, and enables personalized intervention strategies guided by biology rather than behavior.

Pre-Cure is transforming gynecologic oncology treatment selection by turning clinical waste into an actionable precision medicine tool.
Using fluids routinely drained from patients by oncologists, Pre-Cure generates advanced 3D mini-tumour models that accurately replicate each patient’s cancer profile.
These functional ex-vivo models enable precise prediction of treatment response, ensuring the right therapy from the very first line.

Predicta Med is revolutionizing autoimmune diseases care using agentic AI

Self-treat.com is a platform to do emotional self treatment to yourself and to your childs. Expressind and relieving your pains and concerns will increase your energy, joy and give you new perspectives and solutions for your every day life. Always available , everywhere, private and supporting, it is now easy to quickly find balance.

Shela Health is a precision maternal-health company focused on addressing one of the most critical challenges in healthcare today: the early identification and prevention of pregnancy and postpartum complications. More than 25% of pregnancies globally involve a significant complication, many of which are detected too late to enable effective prevention. Shela aims to change this paradigm.

Shela develops advanced predictive models that leverage clinical and multiomics data to identify risk for high-impact conditions such as preeclampsia, gestational diabetes, preterm birth, and fetal growth restriction at the earliest stages of pregnancy. By enabling risk identification weeks earlier than standard practice, Shela shifts maternal care from a reactive model to a proactive, prevention-focused approach, allowing timely intervention when it can most meaningfully improve outcomes. The platform is designed to integrate seamlessly into real-world care pathways, supporting clinicians and health systems while complementing existing standards of care rather than replacing them.

Shela is now beginning the deployment of its first predictive model and is building toward a broader lifecycle platform that spans pregnancy, postpartum, and long-term women’s health.

TIKI100 is a medical device company redefining the management of female urinary incontinence (UI), a condition affecting more than 200 million women worldwide. Its proprietary product, ControlFlow, is a discreet, Bluetooth-enabled smart intraurethral device that enables women to independently control urination while reducing the risk of catheter-associated urinary tract infections (CAUTIs).
Unlike existing solutions, pads, medications, catheters, or surgery that manage symptoms passively or involve invasive interventions, ControlFlow offers an active, user-controlled approach that prioritizes dignity, safety, and quality of life. The device supports guided self-insertion using an integrated optical sensor and mobile application, includes an antibacterial coating, and can remain in-body for up to 30 days. Urination is enabled discreetly using a smart, app-controlled valve.
TIKI100 plans to launch initially through insured clinical channels, with future expansion into OTC and direct-to-consumer markets. The company is raising $3 million to complete development, scale manufacturing, and obtain FDA clearance.

Urielle Medical is developing a non-invasive, single-use, sterile catheter patch for female urine collection designed to reduce reliance on indwelling catheters. The solution combines a disruptive adhesive interface with a low-profile, skin-conformable architecture to support secure placement, comfort, and discretion in hospital and home care workflows. Urielle targets key clinical and operational challenges, including catheter-associated urinary tract infection (CAUTI) risk reduction, improved patient dignity, and easier nursing workflows, especially for bedridden and mobility-limited women. The product is intended for regulated medical device pathways (EU CE marking and US 510(k)). Development is progressing through concept and prototyping toward bench and simulated-use validation, with a focus on performance at the skin-device interface, leakage control, and user-centered usability. Urielle’s approach bridges urological devices, FemTech, and infection-prevention smart patches, with optional sensor-enablement as a future extension.

An AI-Powered Objective Voice-Based Test for Mental Health Detection

Zero Candida is a FemTech company that develops a non-drug blue light therapy in a SMART vaginal diagnostic device, designed for the millions of women suffering from vaginal candidiasis. The device is a novel diagnostic and therapeutic technology platform with a de novo regulatory pathway.
Our technology offers precise and personalized treatment, with No side effects, No prescription, No drugs, At-home treatment and with Digital interaction.
Zero Candida Technologies Inc. (ZCT) is publicly traded in Canada as ZCT, on the OTCQB in the U.S. and the Frankfurt Stock Exchange

Lyra Medical has developed a new implant for the surgical treatment of pelvic organ prolapse (POP). The company’s self-retaining support (SRS) technology eliminates the need for complex anchoring techniques to assure a safe, easy to use and long-term treatment solution. The anchorless solution mimics the physiologic support, pubocervical fascia, restoring pelvic organs to their anatomical and functional location. The SRS Implant is the only product that has delivered exceptional safety and long-term efficacy through clinical trials prior to being approved for general use. The SRS Implant is currently available for use in Europe, Central America and Israel.

A synthetic biology/RNA platform to create therapeutic cancer vaccines- we're focusing on Ovarian Cancer amongst others

Endospot addresses the urgent need for effective endometriosis
treatment that relieves pain without causing hormonal disruption and
severe side effects - limitations that make current therapies
intolerable for many women. Endometriosis is a chronic, painful
disease affecting over 200 million women worldwide in which
uterine-like tissue forms lesions outside the uterus causing
inflammation, pain and infertility. There are no specific molecular
targets in the lesions, and all systemic treatments have these off
target effects.


Endospot is a biotech startup developing a first-in-class, locally
acting treatment. EndoSpot’s patented product is engineered for local
retention in the peritoneal cavity and for sustained release of active
agents that target endometriosis lesions, providing pain relief
without disrupting hormonal balance, preserving fertility and quality
of life.

Feminai is a women led and founded healthcare company dedicated to advancing women's breast health. By combining wearable sensors with artificial intelligence analysis, Feminai empowers women to take control of their breast health.

PrevisionDX is developing innovative technology to assess cardiovascular disease risk using
mammography imaging. By leveraging existing mammogram data, we aim to provide early
cardiovascular risk assessment without additional imaging or procedures, potentially saving lives through earlier intervention.

PeachAI is the smart AI layer transforming everyday biosignal data into continuous
hormone tracking, unlocking vital visibility for millions of women. Our proprietary AI algorithm transforms wearable data into accessible, continuous hormone visibility across the entire female
lifespan.

About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and Asia.

HEMO AI is developing a next-generation IV monitoring platform designed to improve patient safety and clinical decision-making. The company’s first product is a disposable Smart Stopcock for IV/PICC lines, enabling automated and frequent rinsing to reduce inflammation risk, improve line patency, and support safer infusion workflows. Building on this entry product, HEMO AI is developing modular sensor cartridges that allow frequent bedside monitoring of critical blood biomarkers such as hemoglobin, lactate, glucose, and additional analytes. By turning intermittent lab snapshots into continuous trends, HEMO AI aims to support earlier detection of hemorrhage, sepsis, and clinical deterioration across multiple care settings—including hospital wards, surgery, emergency care, and home hospitalization. The platform integrates biomarker monitoring with data analytics and decision-support algorithms to help clinicians identify risk earlier, optimize treatment timing, and improve outcomes. HEMO AI is advancing through preclinical and clinical stages toward regulatory approval and commercialization.

An AI-Powered Objective Voice-Based Test for Mental Health Detection

Pulsenmore (NASDAQ and TASE: PLSM) is a global leader in connected, home-based ultrasound technology, bringing clinical-grade imaging and guided care into the patient’s home. Our telehealth prenatal care platform enables expectant mothers to perform physician-prescribed ultrasound scans remotely, with results reviewed by clinicians as part of an integrated care pathway. This model expands access to care, helps health systems use clinical resources more efficiently, and gives patients and caregivers more flexibility without compromising oversight.
Pulsenmore is the only FDA-Authorized Home Ultrasound. It's approved for commercial use in the U.S., Europe, the UK, Switzerland, Australia, Brazil, Colombia, and Israel.

Beyond prenatal care, our product roadmap includes at-home follicular monitoring for IVF patients, designed to reduce clinic visits while maintaining medical supervision throughout the cycle.

Pulsenmore’s vision is to make ultrasound imaging more accessible and intuitive, extending care beyond the clinic to improve outcomes and support equity in women’s health globally.

OffRa Health is an AI-driven digital health platform helping health systems close the gap between cancer risk identification and timely clinical action. Unlike fragmented tools, OffRa provides an end-to-end solution by identifying individuals at increased risk for cancer and enabling personalized, guideline-based care pathways and follow-up over time.

The platform enables a shift from reactive care to proactive, longitudinal risk management. Built for real-world clinical environments, OffRa integrates into existing workflows to support both patients and their care teams. By helping ensure that at-risk individuals are not missed, and that screening, surveillance, and early diagnosis occur as intended, OffRa addresses one of the most persistent failures in cancer prevention: the loss of at-risk individuals between identification and action.

Currently focused on women’s cancers, OffRa is designed to scale across additional cancer types and populations.

Foraviset is a clinical-stage FemTech company developing a first-in-class, non-hormonal therapeutic approach for women’s health. Its proprietary technology targets the iNOS pathway, addressing a key biological driver of pain and inflammation in uterine disorders. The company’s lead product, Raviset®, is being developed for endometriosis - a widespread condition affecting millions of women worldwide that remains underserved by existing treatments.

Building on this scientific foundation, Foraviset is advancing a family of products designed to expand into additional uterine and women’s health indications. The company has successfully completed Proof of Concept and Phase I clinical studies and is now on the verge of entering Phase II, marking a significant value-inflection point. In parallel, Foraviset is initiating its Series A fundraising round.

Operating in a global women’s health market estimated at over $80 billion, Foraviset combines clinical rigor with a deep human and emotional commitment to improving women’s quality of life - moving beyond temporary or invasive solutions toward meaningful, lasting care.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​